Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy

Modern Rheumatology

Volumn 26, Issue 1, 2016, Pages 80-86

  Tanaka, Yoshiya ^a   Takeuchi, Tsutomu ^b   Miyasaka, Nobuyuki ^c   Sumida, Takayuki ^d   Mimori, Tsuneyo ^e   Koike, Takao ^f   Endo, Kazuhiro ^g   Mashino, Naomi ^g   Yamamoto, Kazuhiko ^h  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f Sapporo Medical Center   (Japan)

^g ZENYAKU KOGYO CO LTD   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

Author keywords

Effi cacy; Lupus nephritis; Phase II study; Rituximab; Safety

Indexed keywords

CHLORPHENIRAMINE MALEATE; CORTICOSTEROID; METHYLPREDNISOLONE; PARACETAMOL; PREDNISOLONE; RITUXIMAB; IMMUNOLOGIC FACTOR;

ADOLESCENT; AGED; ANEMIA; ARTICLE; BRAIN INFARCTION; CHOLECYSTITIS; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRITIS; HUMAN; JAPANESE (PEOPLE); LUPUS ERYTHEMATOSUS NEPHRITIS; MULTICENTER STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; ADULT; CLINICAL TRIAL; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; RITUXIMAB; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84952874500     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2015.1060665     Document Type: Article

References (34)

1. Dooley MA, A ranow C , Ginzler E M. Review of ACR renal criteria in systemic lupus erythematosus. Lupus 2004 ; 13(11) : 857-60.
2. Cervera R , Khamashta M A, F ont J , Sebastiani G D, G il A , Lavilla P , et al ; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 ; 82(5) : 299-308.
3. Moroni G , Quaglini S , Gallelli B , Banfi G , Messa P , Ponticelli C. Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years. Lupus. 2013 ; 22(8) : 810-8.
4. Tanaka Y , Yamamoto K , Takeuchi T , Nishimoto N , Miyasaka N , Sumida T , et al. Amulticenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007; 17(3): 191-7.
5. Keandro M J, E dwards J C, C ambridge G , Ehrenstein M R, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002 ; 46 : 2673-7.
6. Lu TY , Ng KP , Cambridge G , Leandro MJ , Edwards JC , Ehrenstein M, Isenberg DA. Aretrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The fi rst fi fty patients. Arthritis Rheum. 2009 ; 61(4) : 482-7.
7. Jonsdottir T , Gunnarsson I , Mourao AF , Lu TY , van Vollenhoven RF , Isenberg D. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: Pooled data from two cohorts. Rheumatology (Oxford). 2010; 49(8): 1502-4.
8. Melander C , Sallee M , Trolliet P , Candon S , Belenfant X , Daugas E , et al. Rituximab in severe lupus nephritis: Early B-cell depletion aff ects long-erm renal outcome. Clin J Am Soc Nephrol. 2009 ; 4(3) : 579-87.
9. Merrill JT , Neuwelt CM , Wallace DJ , Shanahan JC , Latinis KM , Oates JC , et al. Effi cacy and safety of rituximab in moderatelyto-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 ; 62(1) : 222-33.
10. Rovin B H, F urie R , Latinis K , Looney R J, F ervenza F C, S anchez-Guerrero J, et al. Effi cacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012 ; 64(4) : 1215-26.
11. Tew GW , Rabbee N , Wolslegel K , Hsieh H-J , Monroe JG , et al. Baseline autoantibody profi les predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010 ; 19(2) : 146-57.
12. Hahn B H, M cMahon M A, W ilkinson A , W allace W D, D aikh D I, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012; 64(6): 797-808.
13. Bertsias G K, T ektonidou M , Amoura Z , Aringer M , Bajema I , Berden JHM , et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012 ; 71(11) : 1771-82.
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classifi cation of systemic lupus erythematosus. Arthritis Rheum 1997 ; 40(9) : 1725.
15. Hay EM , Bacon PA , Gordon C , Isenberg DA , Maddison P , Snaith ML , et al. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. QJ Med. 1993 ; 86(7) : 447-58.
16. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum. 2006 ; 54(2) : 421-32.
17. Markowitz GS , D' Agati VD. The ISN/RPS 2003 classifi cation of lupus nephritis: An assessment at 3 years. Kidney Int. 2007 ; 71(6) : 491-5.
18. Terrier B , Amoura Z , Ravaud P , Hachulla E , Jouenne R , Combe B , et al. Safety and effi cacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010 ; 62(8) : 2458-66.
19. Dí a z-Lagares C , Croca S , Sangle S , Vital E M, C atapano F , Martínez-Berriotxoa A, et al.; UK-BIOGEAS Registry. Effi cacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev. 2012 ; 11(5) : 357-64.
20. W eidenbusch M , Rommele C , Schrottle A , Anders H J. Beyond the LUNAR trial. Effi cacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013 ; 28(1) : 106-11.
21. Murray E , Perry M. Off-label use of rituximab in systemic lupus erythematosus: A systematic review. Clin Rheumatol. 2010 ; 29(7) : 707-16.
22. Ramos-Casals M , Soto M J, C uadrado M J, K hamashta M A. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus. 2009 ; 18(9) : 767-76.
23. Ready V , Jayne D , Close D , Isenberg D. B-cell depletion in SLE: Clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther. 2013 ; 15(Suppl 1) : S2.
24. Murphy G , Lisnevskaia L , Isenberg D. Systemic lupus erythematosus and other autoimmune rheumatic diseases: Challenges to treatment. Lancet. 2013 ; 382 : 809-18.
25. Lisnevskaia L , Murphy G , Isenberg D. Systemic lupus erythematosus. Lancet. 2014 ; 384 : 1878-88.
26. Pepper R , Griffi th M , Kirwan C , Levy J , Taube D , Pusey C , et al. Rituximab is an eff ective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009 ; 24(12) : 3717-23.
27. Ezeonyeji A , Isenberg D. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: A steroid-sparing regimen. Rheumatology 2012; 51(3): 476-81.
28. Stone J , Merkel P , Spiera R , Seo P , Langford C , Hoff man G , et al. Rituximab versus Cyclophosphamide for ANCA-associated vasculitis. NEng J Med. 2010 ; 363(3) : 221-32.
29. Joly P , Mouquet H , Roujeau JC , D' lncan M , Gilbert D , Jacquot S , et al. Asingle cycle of rituximab for treatment of severe pemphigus. NEng J Med. 2007 ; 357(6) : 545-52.
30. Iijima K , Sako M , Nozu K , Mori R , Tuchida N , Kamei , K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: A multicentre, double-blind, randomized, placebo-controlled trial. Lancet 2014 ; 384(9950) : 1273-81.
31. Takei T , Itabashi M , Moriyama T , Kojima C , Shiohira S , Shimizu A , et al. Effect of single-dose rituximab on steroid-dependent minimalchange nephrotic syndrome in adults. Nephrol Dial Transplant. 2013 ; 28(5) : 1225-32.
32. Condon M , Ashby D , Pepper R , Cook H , Levy J , Griffi th M , et al. Prospective observational single-centre cohort study to evaluate the eff ectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013 ; 72(8) : 1280-6.
33. Imperial College London. Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroid for Lupus Nephritis (RITUXILUP). NCT01773616. Available from: Www.ClinicalTrials.gov.
34. Houssiau F A , o n behalf of European Working Party on Systemic Lupus Erythematosus Lupus Nephritis Trial Network. RING: Rituximab for lupus nephritis with remission as a goal. NCT01673295. Available from: Www.ClinicalTrials.gov.